Clinical trials: Clear Cell Kidney Cancer
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Trial name
- NCT01672775
- Testing
- AGS-16C3F
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Agensys, Inc.
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear…
- Trial name
- DUAL-NK RCC (NCT07551349)
- Testing
- EB-701/CA9-NK, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.
- Trial name
- NCT05745142
- Testing
- Sunitinib
- Where
- Turkey (Türkiye)
- Volunteers
- 376 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Advanced Clear Cell Renal Cell Carcinoma
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with…
- Trial name
- NCT07097935
- Testing
- HS-10516 + Lenvatinib
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread…
- Conditions
- Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
- Trial name
- NCT07227415
- Testing
- PF-08634404, Ipilimumab, Axitinib
- Where
- 183 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior…
- Trial name
- NCT01668784
- Testing
- Nivolumab, Everolimus
- Where
- 168 sites in United States, Argentina and 22 more
- Volunteers
- 821 people
- Sponsor
- Bristol-Myers Squibb
ccRCC, Clear Cell Renal Cell Carcinoma
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05119335
- Testing
- Oral NKT2152
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- NiKang Therapeutics, Inc.
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
- Trial name
- NCT07300241
- Testing
- NEO-811
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neomorph, Inc
Renal Cell Carcinoma, Clear Cell
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
This study aims to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- SMT112-216 (NCT07877194)
- Testing
- Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab
- Where
- 2 sites in United States, China
- Volunteers
- 100 people
- Sponsor
- Summit Therapeutics
ccRCC, Clear Cell Renal Cell Carcinoma
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib…
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05935748
- Testing
- NKT2152, palbociclib, sasanlimab
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- NiKang Therapeutics, Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC.
- Trial name
- NCT07594106
- Testing
- REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
- Where
- 6 sites in United States
- Volunteers
- 265 people
- Sponsor
- Regeneron Pharmaceuticals
Clear Cell Renal Cell Carcinoma (ccRCC)
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
- Trial name
- OncoCAIX (NCT06840548)
- Testing
- [68Ga]Ga-OncoCAIX
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.